Knight covers the Healthcare sector, focusing on stocks such as Danaher, Harvard Bioscience, and Repligen. According to TipRanks, Knight has an average return of 6.1% and a 47.17% success rate on recommended stocks.
Currently, the analyst consensus on Avantor is a Moderate Buy with an average price target of $34.83, implying a 48.47% upside from current levels. In a report released on September 9, Barclays also maintained a Buy rating on the stock with a $30.00 price target.
Based on Avantor’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $1.91 billion and a net profit of $187.4 million. In comparison, last year the company earned a revenue of $1.86 billion and had a net profit of $157.8 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Avantor, Inc. is a provider of mission critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. It sells materials & consumables, equipment & instrumentation and services & specialty procurement. It operates in more than 30 countries and deliver an extensive portfolio of products and services. The company was founded by John Townsend Baker in 1904 and is headquartered in Radnor, PA.
Read More on AVTR: